DocumentoJDRF Therapeutic Venturescaricato da
sstrumello7395- DocumentoGeneral Foods Corporate Timelinecaricato dasstrumello7395
- DocumentoJDRF, Less Until Nonecaricato dasstrumello7395
- DocumentoWhy Big Pharmaceutical Companies’ Current Nanotech Efforts Should Failcaricato dasstrumello7395
- DocumentoNovo Nordisk Congressional Testimony on Follow-On Biopharmaceuticals Mollerup March 26, 2007caricato dasstrumello7395
- DocumentoEmblem Insulin Formulary Change 2010caricato dasstrumello7395
- DocumentoWhy Nonprofits Fund For-Profit Companies Doing Drug Researchcaricato dasstrumello7395
- DocumentoAgaMatrix & Sanofi-Aventis Enter Global Diabetes Partnershipcaricato dasstrumello7395
- DocumentoHuman insulin prepared by recombinant DNA techniques and native human insulin interact identically with insulin receptorscaricato dasstrumello7395
- DocumentoFDA ISO Standards for BG Meters 06-24-2009caricato dasstrumello7395
- DocumentoBeyond 'I'm a Diabetic', Little Common Groundcaricato dasstrumello7395
- DocumentoHalozyme Therapeutics, Inc. 2009 Investor Day Presentationcaricato dasstrumello7395
- DocumentoJDRF Countdown July 2009caricato dasstrumello7395
- Documento2008-03-24_Asset_EN Paper on Follow-On Biologics Jan. 2007caricato dasstrumello7395
- Documento2008-03-24_Asset_PCMA Summary of en Studycaricato dasstrumello7395
- DocumentoInfluence of insulin antibodies on pharmacokinetics and bioavailability of recombinant human and highly purified beef insulins in insulin dependent diabeticscaricato dasstrumello7395
- DocumentoThe Unique Cytoarchitechture of Human Pancreatic Islets Has Implications for Islet Cell Functioncaricato dasstrumello7395
- DocumentoStatement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings on "Follow-On Biopharmaceuticals"caricato dasstrumello7395
- DocumentoMost Commercial Insulin Assays Fail to Detect Recombinant Insulin Analoguescaricato dasstrumello7395
- DocumentoHow Do We Define Cure of Diabetes?caricato dasstrumello7395
- DocumentoExpanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin isotopecaricato dasstrumello7395
- DocumentoCould Generic Insulin Soon Hit the U.S. Market?caricato dasstrumello7395
- DocumentoClass Action Complaint for Negligence, Products Liability and Punitive Damages Against Eli Lilly & Company and Novo Nordisk A/S Re; Biosynthetic Human Insulincaricato dasstrumello7395
- DocumentoMandated Diabetes Registries Will Not Benefit Persons With Diabetescaricato dasstrumello7395
- DocumentoDetermination of Purity and Identification of Animal Sources of Insulin in Various Insulin Preparationscaricato dasstrumello7395
- DocumentoPeter Van Etten JDRF Letter Recaricato dasstrumello7395
- DocumentoTreatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 yearscaricato dasstrumello7395
- DocumentoDifferent Potencies of Biosynthetic Human and Purified Porcine Insulincaricato dasstrumello7395
- DocumentoQuestions Answers &caricato dasstrumello7395
- DocumentoStem Cells and Diabetescaricato dasstrumello7395
- DocumentoFederal Funding of Stem Cell Researchcaricato dasstrumello7395
Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
